Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 12—December 2022
Dispatch

Myocarditis Attributable to Monkeypox Virus Infection in 2 Patients, United States, 2022

Guillermo Rodriguez-NavaComments to Author , Peter Kadlecik, Thomas D. Filardo, David L. Ain, Joseph D. Cooper, David W. McCormick, Bryant J. Webber, Kevin O’Laughlin, Brett W. Petersen, Supriya Narasimhan, and Harleen K. Sahni
Author affiliations: Stanford University School of Medicine, Stanford, California, USA (G. Rodriguez-Nava); Mid-Atlantic Permanente Medical Group, Rockville, Maryland, USA (P. Kadlecik); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (T.D. Filardo, D.W. McCormick, B.J. Webber, K. O’Laughlin, B.W. Petersen); Mid-Atlantic Permanente Medical Group, Washington DC, USA (D.L. Ain); Santa Clara Valley Medical Center, San Jose, California, USA (J.D. Cooper, S. Narasimhan, H.K. Sahni)

Main Article

Figure 1

Timeline of events for 2 immunocompetent patients with monkeypox complicated by myocarditis, United States. A) A healthy 32-year-old man (patient 1) had chest pain and shortness of breath 7 days after a prodrome of headache, fatigue, malaise, and cervical lymphadenopathy and 2 days after the rash. Symptoms resolved after 10 days of illness onset and 1 day after initiation of tecovirimat. The patient received supportive care only for myocarditis. B) A healthy 37-year-old man (patient 2) had shortness of breath and decreased exercise tolerance 6 days after illness onset with bilateral inguinal lymphadenopathy and 4 days after the rash. Shortness of breath improved after 12 days of illness onset, and exercise tolerance normalized after 20 days. The patient received supportive care only for both monkeypox and myocarditis.

Figure 1. Timeline of events for 2 immunocompetent patients with monkeypox complicated by myocarditis, United States. A) A healthy 32-year-old man (patient 1) had chest pain and shortness of breath 7 days after a prodrome of headache, fatigue, malaise, and cervical lymphadenopathy and 2 days after the rash. Symptoms resolved after 10 days of illness onset and 1 day after initiation of tecovirimat. The patient received supportive care only for myocarditis. B) A healthy 37-year-old man (patient 2) had shortness of breath and decreased exercise tolerance 6 days after illness onset with bilateral inguinal lymphadenopathy and 4 days after the rash. Shortness of breath improved after 12 days of illness onset, and exercise tolerance normalized after 20 days. The patient received supportive care only for both monkeypox and myocarditis.

Main Article

Page created: September 30, 2022
Page updated: November 21, 2022
Page reviewed: November 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external